Istanbul

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis6 trials
• Asthma3 trials
• Atopic dermatitis (eczema)1 trial
• Gaucher disease1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Multiple myeloma1 trial

Phase

• Phase 39 trials
• Phase 25 trials

Status

• Completed7 trials
• Active, not recruiting3 trials
• Terminated3 trials
• Enrolling by invitation1 trial

Lead sponsor

• Sanofi13 trials
• Genzyme, a Sanofi Company1 trial

Running trials

• Enrolling by invitation

  Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

  NCT06609239· Phase 2· Sanofi· Source

• Active, not recruiting

  A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

  NCT06372145· Phase 3· Sanofi· Source

• Active, not recruiting

  SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

  NCT05405166· Phase 3· Sanofi· Source

• Active, not recruiting

  Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

  NCT04879628· Phase 2· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

  NCT06224348· Phase 3· Sanofi· Source

• Completed

  Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

  NCT06102005· Phase 2· Sanofi· Source

• Terminated

  Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

  NCT05245071· Phase 2· Sanofi· Source

• Completed

  Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Phase 3· Sanofi· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

  NCT04410978· Phase 3· Sanofi· Source

• Terminated

  Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

  NCT04059484· Phase 2· Sanofi· Source

• Completed

  Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)

  NCT03560466· Phase 3· Sanofi· Source

• Completed

  Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

  NCT03485677· Phase 3· Sanofi· Source

• Terminated

  A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

  NCT03368664· Phase 3· Genzyme, a Sanofi Company· Source